Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 3/20 | 0.61 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.61 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.61 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL7212015 | 0.82 | LMNA (0.43) | CACNA2D1ALDH1A1CYP1A2CACNB3CACNA1C | |
| Gabapentin SCHEMBL9517493 | 0.78 | CYP1A2 (0.92) | CACNA2D1ALDH1A1CYP1A2USP2LMNA | |
| Pregabalin SCHEMBL15497 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CYP1A2CACNB3CACNA1CPGR | |
| Pregabalin SCHEMBL263450 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CYP1A2CACNB3CACNA1CPGR | |
| SCHEMBL6544499 | 0.78 | CYP1A2 (1.00) | CACNA2D1ALDH1A1CYP1A2USP2LMNA | |
| Pregabalin SCHEMBL2370227 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CYP1A2CACNB3CACNA1CPGR | |
| Gabapentin SCHEMBL8343 | 0.78 | CYP1A2 (1.00) | CACNA2D1ALDH1A1CYP1A2USP2LMNA | |
| Gabapentin SCHEMBL179836 | 0.78 | CYP1A2 (1.00) | CACNA2D1ALDH1A1CYP1A2USP2LMNA | |
| Gabapentin SCHEMBL4030100 | 0.78 | CYP1A2 (1.00) | CACNA2D1ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL466183 | 0.78 | CYP1A2 (1.00) | CACNA2D1ALDH1A1CYP1A2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194397-A1 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| CN-117529323-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2024-02-06 | — | — | CN | disclosed |
| EP-3000465-B1 | T-TYPE CALCIUM CHANNEL INHIBITOR | UNIV KINKI (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-10633358-B2 | T-type calcium channel inhibitor | KINKI UNIVERSITY (JP) | 2020-04-28 | — | — | US | disclosed |
| WO-2020044070-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION COMPRISING TRAMADOL HYDROCHLORIDE AND PREGABALIN, AND USE THEREOF FOR THE TREATMENT OF NEUROPATHIC PAIN | Grünenthal GmbH (DE) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020044140-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION COMPRISING TRAMADOL HYDROCHLORIDE AND PREGABALIN, AND USE THEREOF FOR THE TREATMENT OF NEUROPATHIC PAIN | Grünenthal GmbH (DE) | 2020-03-05 | — | — | WO | disclosed |
| US-20180161388-A1 | SUBSTANCE P, MAST CELL DEGRANULATION INHIBITORS, AND PERIPHERAL NEUROPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180065947-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | UNIV KINKI (JP) | 2018-03-08 | — | — | US | disclosed |
| WO-2017172603-A1 | TOPICAL FORMULATION | TIOGA RESEARCH, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| CN-106687483-A | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors | 诺华股份有限公司 | 2017-05-17 | — | — | CN | disclosed |
| EP-1569895-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005065308-A2 | COMPOSITIONS AND METHODS TO TREAT RECURRENT MEDICAL CONDITIONS | MCDEVITT JASON (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005027850-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005025562-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004089289-A2 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004052844-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052360-A1 | PRODRUGS OF FUSED GABA ANALOGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065947-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1G, CACNA1H, CACNA1I | CACNA2D1 51/4885CACNB3 20/4885CACNA1C 8/4885 |
| US-10633358-B2 | T-type calcium channel inhibitor | CACNA1G, CACNA1H, CACNA1I | CACNA2D1 51/4885CACNB3 20/4885CACNA1C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.